$SLN News

Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate

We Think Silence Therapeutics (NASDAQ:SLN) Needs To Drive Business Growth Carefully

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Silence Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.

Silence Therapeutics Q4 Earnings Assessment

Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate

With 35% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot at stake

Silence Therapeutics Announces Leadership Changes

Silence Therapeutics President And CEO Craig Tooman Steps Down; Chairman Iain Ross Named Interim Leader

One Silence Therapeutics Insider Raised Stake By 15% In Previous Year

Silence Therapeutics: Divesiran Targets High-Burden PV

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

CORRECTION: Silence Therapeutics Q3 EPADS $(0.45) Misses $(0.28) Estimate, Sales $159.000K Miss $4.414M Estimate